The ASCO Post
@ascopost.bsky.social
1.4K followers 950 following 150 posts
News and views from the world of clinical oncology and hematology
Posts Media Videos Starter Packs
ascopost.bsky.social
BART Trial Presented at the ASTRO Annual Meeting: Adjuvant RT after cystectomy + chemo in MIBC improves survival with no excess grade ≥3 toxicity

One of the first large randomized trials to show meaningful pelvic relapse reductions, says Vedang Murthy, MD

ascopost.com/news/septemb...
Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer
Adjuvant radiation therapy after radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from ...
ascopost.com
ascopost.bsky.social
On Sept 29th, Anthony Letai, MD, PhD, was sworn in as the new Director of the National Cancer Institute (NCI).

He is known for his venetoclax research, predictive biomarker development, and work in apoptosis.

ascopost.com/news/septemb...
ascopost.bsky.social
PRISM Trial: first large-scale randomized study of AI in breast cancer screening in the US

📏 Will evaluate effects on cancer detection, recall rates, & radiologist and patient trust

👩‍⚕️Co-PI: Joann Elmore, MD, MPH

🔗 ascopost.com/news/septemb...
ascopost.bsky.social
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell RCC led to extended median PFS without compromising safety.

The median systemic therapy–free survival was 34 months.

Insights from Chad Tang, MD, et al here: ascopost.com/news/septemb...
ascopost.bsky.social
In the latest issue of The ASCO Post, Stuart M. Lichtman, MD, explains how the new @jco-asco.bsky.social guidelines could improve clinical trial reporting and enhanced care for older patients with cancer.

Read more here: ascopost.com/issues/septe...
ascopost.bsky.social
The September 25 issue of The ASCO Post features insights from @iaslc.bsky.social's WCLC and ASCO 2025, perspectives on palliative care integration, geriatric inclusivity in cancer trial data, accelerated aging in childhood cancer survivors, and MORE

Full issue here: ascopost.com/issues/septe...
ascopost.bsky.social
🧠 Association found between moderate/severe traumatic brain injury and risk of developing malignant brain tumors in US civilians (HR = 1.67)

🔢 Relationship confirmed in meta-analysis

✍️ Saef Izzy, MD
ascopost.com/news/septemb...
ascopost.bsky.social
Three leading cancer organizations @ascocancer.bsky.social, @astro-org.bsky.social, & @socsurgonc.bsky.social updated guidelines on postmastectomy radiotherapy based on new evidence.

Expert panel co-chaired by Rachel B. Jimenez, MD & Kathleen C. Horst, MD

ascopost.com/news/septemb...
ascopost.bsky.social
New report from the American Cancer Society, and lead author Tyler Kratzer, MPH, shows:
- Prostate cancer incidence rising 3%/yr (2014–2021), w/ advanced-stage up 4.6-4.8%/yr
- Mortality decline slowed to 0.6%/yr
- Major disparities persist

ascopost.com/news/septemb...
ascopost.bsky.social
Optimizing CAR T-cell therapy: one size does not fit all, says Nirav H. Shah, MD, MSHP

Antigen targeting should align with disease characteristics of B-cell malignancies

ascopost.com/issues/septe...
ascopost.bsky.social
Real-world data on T-DXd rechallenge after grade 1 ILD: pts with breast cancer continued treatment for several months with low ILD recurrence rates

Study authors Kelsey Natsuhara, MD, @hoperugo.bsky.social, et al

ascopost.com/issues/septe...
ascopost.bsky.social
In the September 10 issue of The ASCO Post:
Kenneth C. Anderson, MD of @danafarbernews.bsky.social
offers insights on the CARTITUDE-1 trial and future research for multiple myeloma
ascopost.com/issues/septe...
ascopost.bsky.social
The @fda.gov has approved the gemcitabine intravesical system (Inlexzo) for adults with BCG-unresponsive non–muscle-invasive bladder cancer with CIS with/without papillary tumors.

In the SunRISe-1 trial: complete responses reported in 82%

ascopost.com/news/septemb...
ascopost.bsky.social
The Cancer Planners Forum 2025, hosted by @uiccofficial.bsky.social with @who.int, @iaeaorg.bsky.social, etc held in May 2025 raised urgent global needs for cancer control plans.

Ulrika Årehed Kågström tells The ASCO Post about successes and remaining challenges

ascopost.com/news/septemb...
ascopost.bsky.social
Inside the August Issue of The ASCO Post: insights from the 2025 EHA Congress, 2025 ASCO Annual Meeting, impacts of the Inflation Reduction Act, cardio-oncology risks, and treatment advances in head and neck cancers #hncsm

Read the full issue here: ascopost.com/issues/augus...
ascopost.bsky.social
New cohort data show post-mastectomy implant reconstructions carry a low risk of non-Hodgkin lymphomas of the breast, with a standardized incidence ratio of 5.03.

Corresponding author Alfred Neugut, MD, PhD
@columbiamed.bsky.social

ascopost.com/news/august-...
ascopost.bsky.social
Polish study showed reliance on AI led to decreased adenoma detection by endoscopists in non-AI assisted colonoscopies (28.4% > 22.4%) ⚠️
Study by Krzysztof Budzyń, MD; Yuichi Mori, MD; et al
Commentary from Omer Ahmad, MD

ascopost.com/news/august-...
ascopost.bsky.social
Largest-ever single donation announced: Nike co-founder Phil Knight & Penny Knight to gift $2B to OHSU Knight Cancer Institute, inspired by its president Brian Druker, MD

Donation will allow for full support for every patient, accelerated diagnostics, access to trials

ascopost.com/news/august-...
ascopost.bsky.social
LLS is rebranding as Blood Cancer United on Aug 28 to reflect support for all 100+ blood cancers.
🩸 Broader reach, unified purpose
🩸 New name, same mission
ascopost.com/news/august-...
#HemOnc #BloodCancer
ascopost.bsky.social
Prescribing patterns for cancer therapies rose more after accelerated approval than after regular approval by the FDA, with off-label use remaining uncommon.

Study led by: Ravi B. Parikh, MD, MPP, FACP

Read more → ascopost.com/news/july-20...

#FDAApproval #CancerDrugs
ascopost.bsky.social
⭐️ KEYNOTE-689 trial
Pembrolizumab + surgery & adjuvant chemoradiotherapy for #HeadAndNeckCancer
✔️ Improved event-free & distant metastasis-free survival
🔬 Douglas Adkins, MD; Kevin Harrington, MBBS, PhD
Expert insights included👇
🔗 ascopost.com/news/july-20...
ascopost.bsky.social
🧬 Over 60% of global liver cancer cases may be preventable by targeting viral hepatitis, alcohol use, and MASLD, according to @TheLancet Commission.

👨‍⚕️ Lead contributors include
Hashem B. El-Serag, M.D., M.P.H. et al.

🔗 Learn more: ascopost.com/news/july-20...

#LiverCancerPrevention #GlobalHealth